Evidence map›Paper›PMID 30545971›Full record

ReviewThe European respiratory journal2019

Risk stratification and medical therapy of pulmonary arterial hypertension.

Nazzareno Galiè, Richard N Channick, Robert P Frantz, Ekkehard Grünig, Zhi Cheng Jing, Olga Moiseeva, Ioana R Preston, Tomas Pulido, Zeenat Safdar, Yuichi Tamura and 1 more

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The European respiratory journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05618093 (Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH), which is not on this map. Cited by 410 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
410citing papers in PubMed, 5 pooled it
66.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05618093 nawithdrawnnot on this mapstarted 2023, after this paper: background citation

Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH

TypeinterventionalSponsorUniversity of California, Los AngelesRan2023 to 2024Enrolled0ConditionsPulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary HypertensionArmsNon-invasive hemodynamic measurements
3 · Its place in the literature

Who cites it

410 citing papers in PubMed, 5 syntheses or guidelines pooled it, 830 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Congenital Portosystemic Shunts: A Review.Journal of clinical and translational hepatology · 2026
    Review
  17. Review
  18. Journal of preventive medicine and hygiene · 2026
    Article
  19. Article
  20. Article

350 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 11 institutions in 7 countries.

Nazzareno GalièDept of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Richard N ChannickPulmonary and Critical Care Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Robert P FrantzDept of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Ekkehard GrünigPulmonary Hypertension Center, Thoraxklinic at Heidelberg University Hospital, Heidelberg, Germany.
Zhi Cheng JingState Key Lab of Cardiovascular Disease, FuWai Hospital and Key Lab of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Olga MoiseevaNon-Coronary Heart Disease Dept, Almazov National Medical Research Centre, St Petersburg, Russian Federation.
Ioana R PrestonTufts University School of Medicine, Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Boston, MA, USA.
Tomas PulidoCardiopulmonary Dept, National Heart Institute, La Salle University, Mexico City, Mexico.
Zeenat SafdarPulmonary, Critical Care Division, Houston Methodist Hospital, Weill Cornell College of Medicine, Houston, TX, USA.
Yuichi TamuraDept of Cardiology, International University of Health and Welfare School of Medicine, Tokyo, Japan.
Vallerie V McLaughlinCardiovascular Medicine, The University of Michigan, Ann Arbor, MI, USA.
Cornell University · USFederal Almazov North-West Medical Research Centre · RUFu Wai Hospital · CNHarvard University · USHeidelberg University · DEInternational University of Health and Welfare · JPMayo Clinic in Arizona · USTufts Medical Center · USUniversidad La Salle · MXUniversity of Bologna · ITUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.

Indexed as

Calcium Channel BlockersEndothelin Receptor AntagonistsHumansLung TransplantationPhosphodiesterase 5 InhibitorsPractice Guidelines as TopicPulmonary Arterial HypertensionRandomized Controlled Trials as TopicRisk AssessmentCalcium Channel BlockersEndothelin Receptor AntagonistsPhosphodiesterase 5 Inhibitors

Identifiers

PMID30545971
PMCPMC6351343
OpenAlexW2904385559

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.